Literature DB >> 25006444

Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study.

Peter J Leary1, Nancy S Jenny2, R Graham Barr3, David A Bluemke4, Michael O Harhay5, Susan R Heckbert6, Richard A Kronmal7, João A Lima8, Carmen Mikacenic1, Russell P Tracy2, Steven M Kawut5.   

Abstract

Pentraxin-3 (PTX3) is a protein mediator of innate immunity that is elevated in the setting of left heart disease and pulmonary arterial hypertension. The relationship between PTX3 and right ventricular (RV) structure and function is not known. We included men and women with magnetic resonance imaging assessment of RV structure and function and measurement of PTX3 from the Multi-Ethnic Study of Atherosclerosis, a study of individuals free of clinical cardiovascular disease. Multivariable linear regression estimated associations between PTX3 protein levels and RV measures after adjusting for demographic characteristics, anthropometrics, smoking status, diabetes mellitus, hypertension, and corresponding left ventricular (LV) parameters. Instrumental variable analysis exploiting Mendelian randomization was attempted using two-stage least squares regression. The study sample included 1,779 participants with available PTX3 levels, RV measures, and all covariables. Mean PTX3 level was 2.1 ng/mL. Higher PTX3 was independently associated with greater RV mass and larger RV end-diastolic volume with and without adjustment for the corresponding LV parameters or C-reactive protein (all P < .05). There was no association between PTX3 and RV ejection fraction or stroke volume. Single-nucleotide polymorphisms were not associated with PTX3 protein levels or RV measures after accounting for race. Instrumental variable analysis could not be reliably performed. Higher PTX3 protein levels were associated with greater RV mass and larger RV end-diastolic volume. These associations were independent of common cardiovascular risk factors and LV morphologic changes. Inflammation is associated with differences in the pulmonary circulation-RV axis in adults without clinical cardiovascular disease.

Entities:  

Keywords:  Mendelian randomization; heart failure; inflammation; pulmonary hypertension; right ventricle

Year:  2014        PMID: 25006444      PMCID: PMC4070771          DOI: 10.1086/675988

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  44 in total

Review 1.  Avoiding bias from weak instruments in Mendelian randomization studies.

Authors:  Stephen Burgess; Simon G Thompson
Journal:  Int J Epidemiol       Date:  2011-03-16       Impact factor: 7.196

2.  Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.

Authors:  Adam Fang; Sean Studer; Steven M Kawut; Vivek N Ahya; James Lee; Keith Wille; Vibha Lama; Lorraine Ware; Jonathan Orens; Ann Weinacker; Scott M Palmer; Maria Crespo; David J Lederer; Clifford S Deutschman; Benjamin A Kohl; Scarlett Bellamy; Ejigayehu Demissie; Jason D Christie
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

3.  Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study).

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Catherine L Hough; Richard A Kronmal; Joao A Lima; Robyn L McClelland; Russell P Tracy; Steven M Kawut
Journal:  Am J Cardiol       Date:  2012-09-18       Impact factor: 2.778

4.  Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.

Authors:  Mei Sun; Manyin Chen; Fayez Dawood; Urszula Zurawska; Jeff Y Li; Thomas Parker; Zamaneh Kassiri; Lorrie A Kirshenbaum; Malcolm Arnold; Rama Khokha; Peter P Liu
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

5.  The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling.

Authors:  A Inforzato; S Jaillon; F Moalli; E Barbati; E Bonavita; B Bottazzi; A Mantovani; C Garlanda
Journal:  Tissue Antigens       Date:  2011-04

6.  Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity.

Authors:  Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

7.  ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA).

Authors:  Suzette J Bielinski; James S Pankow; Na Li; Fang-Chi Hsu; Sara D Adar; Nancy Swords Jenny; Donald W Bowden; Bruce A Wasserman; Donna Arnett
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

8.  Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study.

Authors:  Michael O Harhay; Russell P Tracy; Emilia Bagiella; R Graham Barr; Diane Pinder; W Gregory Hundley; David A Bluemke; Richard A Kronmal; Joao A C Lima; Steven M Kawut
Journal:  Int J Cardiol       Date:  2013-08-09       Impact factor: 4.164

9.  Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction.

Authors:  Monica Salio; Stefano Chimenti; Noeleen De Angelis; Fabiola Molla; Virginia Maina; Manuela Nebuloni; Fabio Pasqualini; Roberto Latini; Cecilia Garlanda; Alberto Mantovani
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

10.  Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension.

Authors:  Yuichi Tamura; Tomohiko Ono; Masataka Kuwana; Kenji Inoue; Makoto Takei; Tsunehisa Yamamoto; Takashi Kawakami; Jun Fujita; Masaharu Kataoka; Kensuke Kimura; Motoaki Sano; Hiroyuki Daida; Toru Satoh; Keiichi Fukuda
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more
  6 in total

1.  Estrogen receptor-α prevents right ventricular diastolic dysfunction and fibrosis in female rats.

Authors:  Tik-Chee Cheng; Jennifer L Philip; Diana M Tabima; Santosh Kumari; Bakhtiyor Yakubov; Andrea L Frump; Timothy A Hacker; Alessandro Bellofiore; Rongbo Li; Xin Sun; Kara N Goss; Tim Lahm; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

2.  Subclinical changes in MRI-determined right ventricular volumes and function in subjects with prediabetes and diabetes.

Authors:  Hannah Patscheider; Roberto Lorbeer; Sigrid Auweter; Anina Schafnitzel; Christian Bayerl; Adrian Curta; Wolfgang Rathmann; Margit Heier; Christa Meisinger; Annette Peters; Fabian Bamberg; Holger Hetterich
Journal:  Eur Radiol       Date:  2018-02-08       Impact factor: 5.315

Review 3.  Biomarkers of Key Biological Pathways in CVD.

Authors:  Nancy Swords Jenny; Nels C Olson; Matthew A Allison; Dena E Rifkin; Lori B Daniels; Ian H de Boer; Christina L Wassel; Russell P Tracy
Journal:  Glob Heart       Date:  2016-09

4.  Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients.

Authors:  Joshua M Diamond; Kristy Ramphal; Mary K Porteous; Edward Cantu; Jason D Christie; Steven M Kawut
Journal:  J Heart Lung Transplant       Date:  2017-12-20       Impact factor: 10.247

5.  Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism.

Authors:  Akira Naito; Nobuhiro Tanabe; Takayuki Jujo; Ayako Shigeta; Toshihiko Sugiura; Seiichiro Sakao; Keiichi Ishida; Koichiro Tatsumi
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

6.  Pentraxin-3 Levels Relate to the Wells Score and Prognosis in Patients with Acute Pulmonary Embolism.

Authors:  Haotian Yang; Jun Zhang; Ying Huan; Yawei Xu; Rong Guo
Journal:  Dis Markers       Date:  2019-03-12       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.